Deletion of 12/15-Lipoxygenase Alters Macrophage and Islet Function in NOD-\textit{Alox15}^{null} Mice, Leading to Protection against Type 1 Diabetes Development

Shamina M. Green-Mitchell\textsuperscript{1}, Sarah A. Tersey\textsuperscript{2}, Banumathi K. Cole\textsuperscript{1}, Kaiwen Ma\textsuperscript{1}, Norine S. Kuhn\textsuperscript{1}, Tina Duong Cunningham\textsuperscript{3}, Nelly A. Maybee\textsuperscript{5}, Swaru K. Chakrabarti\textsuperscript{1}, Marcia McDuffie\textsuperscript{4,5}, David A. Taylor-Fishwick\textsuperscript{1,6}, Raghavendra G. Mirmira\textsuperscript{3}, Jerry L. Nadler\textsuperscript{1,5}, Margaret A. Morris\textsuperscript{1,6,}\*  

\textsuperscript{1} Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia, United States of America, \textsuperscript{2} Department of Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, \textsuperscript{3} Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, Virginia, United States of America, \textsuperscript{4} Department of Microbiology, University of Virginia, Charlottesville, Virginia, United States of America, \textsuperscript{5} Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of America, \textsuperscript{6} Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia, United States of America

Abstract

\textbf{Aims:} Type 1 diabetes (T1D) is characterized by autoimmune depletion of insulin-producing pancreatic beta cells. We showed previously that deletion of the 12/15-lipoxygenase enzyme (12/15-LO, \textit{Alox15} gene) in NOD mice leads to nearly 100 percent protection from T1D. In this study, we test the hypothesis that cytokines involved in the IL-12/12/15-LO axis affect both macrophage and islet function, which contributes to the development of T1D.

\textbf{Methods:} 12/15-LO expression was clarified in immune cells by qRT-PCR, and timing of expression was tested in islets using qRT-PCR and Western blotting. Expression of key proinflammatory cytokines and pancreatic transcription factors was studied in NOD and NOD-\textit{Alox15}^{null} macrophages and islets using qRT-PCR. The two mouse strains were also assessed for the ability of splenocytes to transfer diabetes in an adoptive transfer model, and beta cell mass.

\textbf{Results:} 12/15-LO is expressed in macrophages, but not B and T cells of NOD mice. In macrophages, 12/15-LO deletion leads to decreased proinflammatory cytokine mRNA and protein levels. Furthermore, splenocytes from NOD-\textit{Alox15}^{null} mice are unable to transfer diabetes in an adoptive transfer model. In islets, expression of 12/15-LO in NOD mice peaks at a crucial time during insulitis development. The absence of 12/15-LO results in maintenance of islet health with respect to measurements of islet-specific transcription factors, markers of islet health, proinflammatory cytokines, and beta cell mass.

\textbf{Conclusions:} These results suggest that 12/15-LO affects islet and macrophage function, causing inflammation, and leading to autoimmunity and reduced beta cell mass.

Citation: Green-Mitchell SM, Tersey SA, Cole BK, Ma K, Kuhn NS, et al. (2013) Deletion of 12/15-Lipoxygenase Alters Macrophage and Islet Function in NOD-\textit{Alox15}^{null} Mice, Leading to Protection against Type 1 Diabetes Development. PLoS ONE 8(2): e56763. doi:10.1371/journal.pone.0056763

Copyright: © 2013 Green-Mitchell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by grants from the Juvenile Diabetes Research Foundation (www.jdrf.org, 40-2009-711), and the American Diabetes Association (www.diabetes.org, 7-11-JF-33). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: morrisma@evms.edu

Introduction

Type 1 diabetes (T1D) is a complex autoimmune disease in which immune cells react against insulin-producing beta cells within the pancreatic islets of Langerhans [1,2], leaving affected individuals dependent upon exogenous insulin for life, and at high risk for developing serious cardiovascular and microvascular complications. Female NOD mice develop spontaneous type 1-like diabetes that mimics human disease [3]. We previously showed that the \textit{Alox15} gene locus contributes to diabetes pathogenesis in the NOD model using a congenic strain lacking \textit{Alox15} (NOD-\textit{Alox15}^{null}) [4]. \textit{Alox15} deletion leads to 98 percent protection from diabetes in female NOD mice. Furthermore, macrophage infiltration and CD4\textsuperscript{+} T cell infiltrates into the pancreas were significantly reduced in NOD-\textit{Alox15}^{null} mice [4].

The murine \textit{Alox15} gene encodes the 12/15-lipoxygenase (12/15-LO) enzyme, which is involved in the oxygenation of arachidonic and linoleic acids to the inflammatory mediators 12-S-hydroperoxyeicosatetraenoic acid and 13-(S)-hydroxy-9Z11E-octadecadienoic acid. Unstable 12-S-hydroperoxyeicosatetraenoic acid is highly toxic, and is almost immediately converted to the more stable 12-HETE (hydroxyeicosatetraenoic acid) by glutathione peroxidase [5-7]. 12-HETE can activate a signaling cascade that can lead to cytokine-induced cell damage [8]. Downstream generation of IL-12 by 12/15-LO products presumably leads to T cell activation and phosphorylation of signal transducers and activators of transcription 4 (STAT4) [9,10]. Phosphorylated
STAT4 leads to the production and activation of many downstream proinflammatory cytokines, which can contribute to the destruction of pancreatic beta cells and the autoimmunity seen in T1D [8,11].

Macrophages are a primary source of IL-12, and global deletion of 12/15-LO in C57BL/6j mice has been demonstrated to reduce IL-12 production [12,13]. Downstream effectors of the 12/15-LO pathway can lead to a positive feedback loop, perpetuating the inflammatory response [9]. Therefore, reduced activation of the IL-12/STAT1 cascade may be a potential mechanism for reduced autoimmunity and inflammation in NOD- Alox15null mice.

12/15-LO expression has also been seen in pancreatic beta cells of both humans and rodents [8,14,15]. It is possible that islet production of 12-HETE could lead to significant islet damage in the context of inflammatory stress, leading to beta cell dysfunction or loss of viability [14,15]. Furthermore, recent evidence shows that NOD mice experience intrinsic beta cell dysfunction prior to diabetes onset [16]. When Alox15 is specifically deleted in islets of mixed background mice, these mice are protected from developing type 1-like diabetes following streptozotocin treatment [17].

In this study, we performed experiments to further clarify the in vivo relevance and possible mechanisms for the role of 12/15-LO in T1D induction in NOD mice. We investigated the role 12/15-LO expression plays in the development of autoimmune responses in T1D, with a specific emphasis on macrophage expression. We also studied the effects of 12/15-LO expression on islet health and function. The results of our studies indicate a role for 12/15-LO in both macrophage and islet function in the development of T1D.

**Methods**

**Ethics Statement**

All mice were treated in accordance with the “Principles of laboratory animal care” [NIH publication no. 85–23], AAALAC, and IACUC guidelines at the Eastern Virginia Medical Center.

**Mice.** Female NOD/ShiLtJ (NOD, used at 4–16 weeks old) and NOD.CB17-Prkd<sup>scid</sup>/J (NOD.<br>scid, ordered at 8 weeks old from The Jackson Laboratory, Bar Harbor, ME), NOD-Alox15<sup>3<sup>rd</sup></sup> (used at 4–16 weeks old), and NOD-Alox15<sup>null</sup>.<br>scid mice (colonies maintained on-site, used at 8–10 weeks old) were housed under SPF conditions. <br>scid strains were fed antibiotic chow (TD.07194-<br>Uniprim diet) every other week to minimize infections with environmental bacteria. Blood glucose of NOD mice was monitored twice weekly by a One Touch Ultra blood glucose monitor (Lifescan, Inc., Milpitas, CA) beginning at 10 weeks of age, and two consecutive daily readings above 250 mg/dL indicated overt diabetes.

**Islet & Acinar Isolation**

Pancreatic islets from NOD and NOD-Alox15<sup>null</sup> mice were isolated by collagenase digestion and Histopaque (Sigma-Aldrich, St Louis, MO, USA) centrifugation using a modified version of a previously published protocol [18]. Islets were used the same day for qRT-PCR and Western blots.

**Cell Isolations**

T and B cells were isolated from spleen by mouse subset positive selection kits from Stem Cell Technologies (Vancouver, BC, Canada). Resulting populations were >97% pure.

**qRT-PCR.** RNA and cDNA were prepared as described [19]. For quantitative measurement of most RT-PCR products, TaqMan probes (Applied Biosciences, Carlsbad, CA, USA) were used with Jump Start Taq Polymerase (Sigma-Aldrich). The PCR conditions for all genes except 12/15-LO were: denaturation at 95°C for 30 s, annealing and extension at 60°C for 60 s at 40 cycles. Reactions were performed in triplicate and data were normalized to the actin housekeeping gene. Expression levels were presented as either fold change of transcripts compared to time matched controls, or as 1/ΔCt. 12/15-LO mRNA expression was quantitatively measured as previously described [19] using SYBR green dye (Invitrogen, Carlsbad, CA, USA) with the following primer sequences: Forward, 5′-GTCCTCAGGGCTGTTCAGGA-3′; reverse, 5′-GTCCATTGTGCCCCAGAACTCT-3′ decreasing the annealing temperature to 60°C. Expression was normalized to β-actin expression, and expressed as ΔCt.

**TH17 PCR Array**

A mouse TH17 Array was purchased from SABiosciences (Frederick, MD, USA) and used as directed. Reactions were analyzed using a two-step cycling program on a Bio-Rad CFX96 real-time system (Hercules, CA, USA). Results were validated by quantitative RT-PCR, described above.

**Western Blotting**

Islet protein extracts from 200 mouse islets (NOD and NOD-Alox15<sup>null</sup>) were isolated for western blotting (10% gel). 15 μg protein was used to ensure equal loading per lane, followed by blotting with rabbit anti-IL-12 (Santa Cruz, Santa Cruz Biotechnology, CA, USA), and rabbit leukocyte 12-LO Ab [8].

**Thioglycollate-Induced Peritoneal Macrophages**

16-week old female NOD and NOD-Alox15<sup>null</sup> mice were injected i.p. with 2 ml of 4% thioglycollate (Sigma-Aldrich). Cells were harvested three days later, allowed to settle for 3 hours, and cultured in RPMI with 10% FBS for 24 hours, followed by culture in RPMI with 0.2% BSA. After 4 days, cells were harvested and mRNA isolated for analysis by RT-PCR (described above). For protein assays, 12 week old NOD or NOD-Alox15<sup>null</sup> mice were used. Cells were allowed to adhere for 3 hours, then treated with LPS (10 ng/ml) and IFN-γ (100 ng/ml). Cells were harvested after 24 hours. Both supernatants and cell pellets were saved for analysis by ELISA.

**ELISA**

IL-1β protein levels were measured in cell supernatants per the manufacturer’s instructions (eBioscience Platinum ELISA, San Diego, CA, USA). Total STAT4 protein was measured in cell lysates per the manufacturer’s instructions (MyBioSource, San Diego, CA, USA). Data are presented as a ratio of pg of the specific protein tested compared to μg of total protein.

**Intracellular Flow Cytometry**

IL-12p35 and IL-12p40 levels were measured in bone marrow macrophages. Cells were plated in 6 well plates, and incubated overnight. Subsequently, cells were either treated with IFN-γ (100 ng/ml) for 6 hours at 37°C, then LPS (10 ng/ml) overnight, or left untreated in media alone. Brefeldin A was added to both groups to prevent secretion of cytokines. Data are expressed as fold-change of stimulated cell expression over untreated cells, after accounting for staining in isotype-matched control antibodies.

**Immunofluorescent Staining of Frozen Tissues**

Tissues were snap frozen for sectioning, and staining as described [4]. Stained slides were viewed on a Zeiss Axio Observer Z1 microscope, and analyzed with Zeiss AxioVision software (Carl Zeiss MicroImaging, Thornwood, NY, USA).
Scoring of Insulitis

Briefly, frozen sections were stained as described above, and blindly scored for insulitis (level of mononuclear cell infiltration), granulation (level of insulin staining), and the presence of either CD4⁺ or Foxp3⁺ T cells as described previously [4]. The scoring scale ranges from 0 (no insulitis/granulation/T cells) to 3 (maximal insulitis/granulation/T cells).

Beta Cell Area

Beta cell area was calculated as described previously [20], but with some modifications. Pancreata from 3–5 mice per group were rapidly dissected, fixed in 4% paraformaldehyde, paraffin-embedded, and longitudinally sectioned. Three sections per pancreas (approximately 75 μm apart) were immunostained for insulin and counterstained with hematoxylin as described previously [21]. Digital images were acquired on an Axio-Observer Z1 microscope fitted with an AxioCam high-resolution color camera. Relative beta cell area was calculated using Axio-Vision Software.

Measurement of Total Serum Cytokines

Serum was collected following cardiac puncture at the time of euthanasia as described [22]. The Luminex system (Millipore) was used to analyze serum samples using a multiplex kit for detecting mouse cytokines and chemokines from Millipore (Billerica, MA, USA).

Adoptive Transfer

Total splenocytes (20×10⁶ cells) from age-matched donors (13 weeks of age at donation) were injected via the lateral tail vein into recipient NOD.scid or NOD-12/15-LO−/−.scid mice, based on previous studies [23,24]. Blood glucose was monitored pre- and post-transfer for up to 10 weeks to ascertain disease progression.

Cytokine Production in Beta Cells

BTC3 cultured to near-confluency were either left untreated, or treated for 6 hours at 37°C with a triple cytokine cocktail containing IL-1β (0.5 ng/ml), TNF-α (1 ng/ml) and IFN-γ (10 ng/ml). Cells were harvested, mRNA was extracted, cDNA made, and the gene expression measured using RT-PCR as described above.

Glucose Stimulated Insulin Secretion (GSIS)

MIN6 beta cells were used as previously described [25], but treated with 2.5 ng/ml of IL-12p70 as the experimental condition. Insulin concentrations were determined using an Insulin ELISA kit (MERCODIA AB, Uppsala, Sweden). The data is shown as insulin secretion normalized to total protein. To graph in this way we first used the Lowry protein assay to calculate the “Total protein” in μg/μl. We then converted the “Total insulin” secretion values from the ELISA to μg/μl based on a formula given in the manufacturer’s instructions. To get “Insulin secretion normalized to total protein”, we divided the value for “Total protein” by the value for “Total insulin” from corresponding wells.

Statistics

The time to diabetes development was analyzed using the Kaplan-Meier method to construct survival curves. Breslow-Wilcoxon tests were used to determine whether differences between the 2 experiments/strains were significant. Statistical tests were performed using SAS 9.3 (the SAS Institute) with a significant level of alpha = 0.05. Additionally, statistically significant differences were determined by the use of two-tailed Student’s T test, where appropriate, or ANOVA followed by post-hoc testing. Significant differences in all cases were determined by p<0.05.

Results

Characterization of 12/15-LO in Immune Cells and Effects on Gene Expression

In order to characterize the mechanism of protection from diabetes progression in NOD-Alox15−/− mice, we first investigated several aspects of the timing and cellular location of the Alox15 gene expression in NOD mice, and how alterations in expression might affect inflammation. We concentrated on expression in two main cell types: macrophages and pancreatic islets.

Previously, we showed that macrophages of NOD mice clearly express 12/15-LO mRNA and protein, while 12/15LO expression in NOD-Alox15−/− macrophages was absent [4]. Here, we tested 12/15-LO mRNA expression levels in age-matched, isolated peritoneal macrophages, CD4⁺ and CD8⁺ T cells, and B cells. 12/15-LO was seen almost exclusively in macrophages compared to essentially undetectable levels in lymphocytes (Figure 1A). Therefore, macrophages, but not B and T cells, are most likely to participate in the generation of the Alox15 gene products. We then investigated how 12/15-LO expression affected macrophage proinflammatory cytokines downstream of 12/15-LO, including MCP-1, IL-1β, STAT-4, and IL-12p40. STAT-4 and IL-12p40 mRNAs were significantly decreased in 12/15-LO deficient macrophages (Figure 1B). To confirm that similar results were seen in protein levels of the downstream mediators, we performed ELISAs (MCP-1, IL-1β, and STAT4) or intracellular staining (IL-12p70). NOD-Alox15−/− macrophages exhibited significantly lower levels of IL-1β, total STAT4 (Figure 1C), and IL-12p70 proteins (Figure 1D). MCP-1, similar to the mRNA levels, was not decreased in the NOD-Alox15−/− macrophages (data not shown).

T Cell Function in the Absence of 12/15-LO

To test whether deletion of 12/15 LO in macrophages affects T cell ability to transfer disease, we performed adoptive transfer assays by injecting unfractionated splenocytes from either NOD or NOD-Alox15−/− mice into NOD.scid or NOD-Alox15−/−.scid mice (Figure 2A). These results show that pre-diabetic NOD donor splenocytes are able to transfer disease to both NOD.scid and NOD-Alox15−/−.scid recipients (Figure 2A). In contrast, splenocytes from NOD-Alox15−/− donors did not transfer disease. Interestingly, NOD-Alox15−/−.scid recipients showed a slight, but statistically significant delay in disease onset compared to NOD.scid recipients following the adoptive transfer of NOD splenocytes (p<0.03 by the Wilcoxon test). Consistent with a dramatic difference in disease transmission, serum cytokines from recipients given NOD donor cells showed significant increases in IL-1α, IL-5, IL-10, IP-10, RANTES, IL-12p70, and IL-17A compared to those given NOD-Alox15−/− donor cells (Figure 2C).

Further characterization of the infiltration in adoptive transfer hosts allowed us to determine that CD4⁺ T cells are significantly increased in NOD.scid mice injected with NOD donor cells (Figure 3A) as compared to those injected with NOD-Alox15−/− donor splenocytes (Figure 3B). Frozen pancreas sections were stained with anti-insulin (red) and anti-CD4 antibodies (green), as well as with the Hoechst nuclear stain (blue). Representative sections are shown in Figure 3A and B. These studies showed that insulin, or the levels of infiltrating mononuclear cells, was significantly increased, and comprised of CD4⁺ T cell infiltration. Granulation, which is an indicator of the amount of insulin stored
in beta cell granules, was significantly lower in NOD.scid hosts receiving NOD splenocytes (quantified in Figure 3C). Sections were also stained with anti-insulin (green) and anti-Foxp3 antibodies (red) and Hoechst nuclear stain (blue) in order to assess the levels of regulatory T cells following adoptive transfer of either NOD or NOD-Alox15null donor splenocytes (Figure 3D & E). When Foxp3 was globally scored, we saw no difference between the two groups. However, we investigated the presence of Foxp3+ cells in the context of insulitis and found that there was a significant increase in Foxp3+ cells when additional insulitis was present (Figure 3F). These data demonstrate that, in the presence of infiltrating lymphocytes, there is a significant increase in the levels of Foxp3+ cells. This may indicate that 12/15-LO negatively affects the development or recruitment of regulatory T cells during the islet inflammatory processes of type 1 diabetes.

12/15-LO Expression Affects Islet Mass and Functional Gene Expression

We next wanted to explore 12/15-LO expression in islets. Previous studies have shown 12/15-LO is expressed in both mouse and human islets [8,14,15]. NOD islets show 12/15-LO expression at both the mRNA and protein level (Figure 4). mRNA expression increased steadily and significantly as the mice aged (Figure 4A), while protein levels peaked at 8 weeks of age (Figure 4B).

Investigations into islet viability suggested that NOD-Alox15null mice have more viable islets for a longer period of time. Calculation of the percent of beta cells contributing to the total pancreatic area shows that absence of 12/15-LO is associated with increased beta cell mass in NOD-Alox15null mice (Figure 5). Even at 4 weeks of age, NOD-Alox15null mice exhibit a significantly higher percentage of beta cells per total pancreatic area as compared to NOD mice. The percentage of beta cells per total pancreas section remained similar as the NOD-Alox15null mice aged, but decreased in NOD mice as they aged and became diabetic.

Focused gene expression was used to ascertain islet health on a molecular level. Islets from the two NOD background strains (n = 4 per strain per time point) were tested by qRT-PCR for mRNA expression of the islet-specific factors (GLUT2, Pdx1), and the mitochondrial stress factor UCP2 (Table 1). GLUT2 mRNA expression was similar in both NOD and NOD-Alox15null islets at 4 and 8 weeks. However, at 12 weeks, the expression of GLUT2 in NOD-Alox15null islets was significantly higher than in wild type NOD islets. Pdx1 mRNA expression was readily detected in islets from both strains at 4 weeks, but in NOD islets, Pdx1 expression decreased significantly by 8 weeks. However, Pdx1 expression increased steadily in NOD-Alox15null islets as the mice aged. Gene
expression of the mitochondrial stress factor UCP2 increased slightly as wild type NOD mice aged, but remained relatively level in NOD-Alox15null islets.

A TH17 PCR array was used to evaluate key inflammatory cytokines in islets from Alox15null and wild type female NOD mice (Table S1, n = 3 mice per strain per time point). The mRNA levels of several molecules were decreased in the absence of 12/15-LO in

---

**Figure 2. Adoptive transfer of NOD and NOD-Alox15null splenocytes.** Donor cells were either non-diabetic NOD or NOD-Alox15null donor splenocytes transferred into NOD.scid or diabetic NOD and non-diabetic NOD-Alox15null donor splenocytes transferred into NOD-Alox15null.scid recipients. All donors were at least 13 weeks old at the time of transfer. C) Total serum cytokine measurements of adoptive transfer hosts. Data are pooled from either 2 (NOD-Alox15null.scid recipients) or 3 (NOD.scid recipients) experiments. For NOD versus NOD-Alox15null donor splenocytes into NOD.scid mice, p≤0.0001, or p≤0.0003 for NOD-Alox15null.scid recipients. NOD into NOD.scid recipients. Difference between recipients given NOD donor cells, p≤0.03.

doi:10.1371/journal.pone.0056763.g002
islets. Validation of the TH17 array by qRT-PCR demonstrated two different expression patterns for the genes tested. In NOD-Alox15null islets, IL-12Rb2, IL-12p35, IL-12p40, and STAT4 all decreased over time, with significant decreases seen by 8 weeks compared to NOD islets (Figure 6A, C, D, and E). In the second pattern grouping, expression levels reached a nadir at 8 weeks, followed by a slight increase at 12 weeks, with levels still remaining lower than age-matched NOD controls. IL-12Rb1, IFN-c, TNF-a, and IL-1b fall into this group (Figures 6B, F, G, and H). These results show that islet-specific proinflammatory cytokine responses are significantly blunted in the absence of 12/15-LO in NOD-Alox15null mice compared to NOD controls, indicating a clear role for the 12/15 lipoxygenase gene in the development of inflammatory responses in T1D.

While some of the increased inflammation in NOD islets is due to the presence of immune cells (i.e., 10-fold increase in CD3e mRNA over NOD-Alox15null islets), a portion of the inflammatory response starts in the islet itself. Since beta cells cannot be separated from infiltrating cells in NOD mouse islets, we utilized a murine beta cell line, 𝜏TC3, to test for beta cell-specific cytokine expression under normal and inflammatory conditions. 𝜏TC3 cells show an increase in IL-23p19, IL-12Rb1 & 2, and STAT4 following triple cytokine treatment (IFN-c, TNF-a, and IL-1b) (Figure 7). IL-22, which is produced only by lymphoid cells [26], does not change following the same treatment. Data are expressed as fold change of each target over untreated, paired controls (n = 8).

We found no significant differences in 12/15-LO or cytokine mRNA expression in the spleen, lymph nodes, or fat for any of the genes tested in NOD and NOD-Alox15null tissues at 4, 8, and 12 weeks of age (Figure S1, data not shown).

**Functional Assays Reveal that IL-12 Negatively Affects Islet Health**

IL-12p70 is a downstream product of the 12/15-LO pathway [6], and is decreased in the absence of 12/15-LO. Since we demonstrated that mRNA levels of both IL-12 subunits and their respective receptors were increased in NOD over NOD-Alox15null islets, we utilized CD4+ T cell infiltration after adoptive transfer. Representative pictures of frozen pancreas sections stained with anti-CD4 (green), anti-insulin (red), and Hoechst nuclear dye (blue) from NOD.scid host mice receiving either (A) NOD (n = 5) or (B) NOD-Alox15null (n = 5) donor cells. Results are quantified in (C). Foxp3+ T cells are present after adoptive transfer. Representative pictures of frozen pancreas sections stained with anti-Foxp3 (red), anti-insulin (green), and Hoechst nuclear dye (blue) from NOD.scid host mice receiving either (D) NOD (n = 5) or (E) NOD-Alox15null (n = 5) donor splenocytes. (F) Quantified results with the presence of Foxp3 expressed in a ratio with insulitis levels. *p<0.05. These data represent 3 experiments with n = 5 mice per group.

doi:10.1371/journal.pone.0056763.g003
islets, we wanted to isolate potential effects on isolated beta cells. Therefore, we tested the effect of IL-12 on the MIN6 beta cell line, which exhibits characteristics of GSIS similar to those of normal islets [25]. MIN6 cells treated with 50 ng/ml of IL-12 have impaired insulin secretion in response to both low and high levels of glucose (Figure 8). Data are expressed as insulin secretion as normalized to total cellular protein levels. Additional evidence from our group suggests that this is also true in rat and human beta cells [27].

Discussion

The goal of our studies has been to identify which source of 12/15-LO is more important in the pathogenesis of T1D. The key finding of the present study is that global deletion of Alox15 modified both immune cell and islet components in NOD mice. NOD-Alox15null mice exhibit significant reduction in pancreatic inflammation as compared to age-matched NOD mice. Subsequently, this translated to preserved beta cell volume in NOD-Alox15null mice.

We found that macrophages, but not B and T cells, express 12/15-LO mRNA. This is consistent with previous studies in other models showing expression of 12/15LO in macrophages, but not in Tor B cells [9,13]. Together, with our previous study of 12/15-LO mRNA and protein levels in NOD macrophages, it was not surprising to find that 12/15-LO deficient macrophages produce significantly reduced amounts of STAT4 and IL-12p40, which are downstream of 12/15-LO. Surprisingly, MCP-1 levels did not vary between the two NOD strains. Given previous results, this was unexpected [28]. It is possible that strain differences between NOD and C57BL/6 mice lead to this difference.

Functionally, it appears that Alox15null macrophages are unable to stimulate the downstream autoimmune response as tested by adoptive transfer. 12/15-LO expression levels, presumably in macrophages or dendritic cells in the NOD mouse model, likely affect the ability of T cells to transfer disease. NOD-derived donor splenocytes are capable of transferring T1D, even when originating from a non-diabetic mouse. In contrast, non-diabetic NOD-Alox15null donor cells are unable to transfer disease, suggesting that macrophage Alox15 expression greatly influences the development of the autoimmune response in the NOD mouse strain. This influence may be exerted through the expression and signaling of IL-12 and STAT4, which are key signals driving Th1 cell development. In the absence of 12/15-LO, IL-12 production and STAT4 signaling are significantly reduced. The absence of STAT4, in both streptozotocin-induced and spontaneous diabetes, protects against the development of diabetes [11,29,30]. Additionally, lisofylline, which inhibits STAT4 activation, also provides protection against diabetes development [31]. Reductions in IL-12 and STAT4 signaling have been shown to reduce the induction of T-bet, and subsequently production of IFN-γ [32,33]. This type of reduction could result in the skewing towards more protective Th2-like immune responses. Our data indicate that these effects include alterations in Foxp3+ regulatory T cells, which are increased around the islets during insulitis in the absence of 12/15-LO [4]. It is possible that the increase in Foxp3+ cells aids in
GLUT2, important in glucose sensing by beta cells, was increased as a result of this expression. To investigate cellular stress of islets, we felt it was pertinent to address subsequent changes in islets as well, since 12/15-LO was found in murine and human islets [14,15], and is involved in the pathogenesis of T1D of NOD mice. Indeed, this is the time during typical age of onset of most inflammatory processes in the pancreas. Since 12/15-LO is involved in the islet health early in development. Since 12/15-LO is involved in the development of the inflammatory processes in the inner mitochondrial membrane, is responsible for the production of ATP during oxidative phosphorylation in the electron transport chain, and is essential for insulin secretion [37]. The overexpression of UCP2 at 12 weeks in the NOD mice may reflect overcompensation of UCP2 in an attempt to override the impaired glucose secretion, or it may be a side effect of cellular stress caused by the highly inflamed environment.

Proinflammatory cytokines increased in the islets of aging NOD mice, but not in NOD-Alox15null mice. Mediators from the IL-12/IFN-γ pathway (IFN-γ, IL-12p40, IL-12p35, IL-12Rβ1, IL-12Rβ2 and STAT4), TNF-α, and IL-1β were all significantly down-regulated in NOD-Alox15null islets. In addition, NOD-Alox15null mouse islets did not show an accumulation of Th1/Th17 cytokines as they aged compared to the NOD mouse islets. Many of these cytokines are involved in mediating inflammatory responses. Up-regulation of these cytokines in the 12-week-old NOD mouse islets is consistent with the idea that IL-12 axis cytokines are major contributors to the destruction of beta cells in T1D [38]. The exact roles of these cytokines in T1D will require further study, but it is of interest that deletion of 12/15-LO reduced cytokine expression in NOD-Alox15null islets. Although some of these cytokines may be attributed to the lymphocytic infiltration in the islets at the time of harvest, we have also shown that mouse beta cells themselves are capable of producing inflammatory cytokines, as βTC3 cells treated with a triple cytokine cocktail show increased cytokine and cytokine receptor expression following treatment.

Functional analysis of the effects of IL-12, a downstream product of 12/15-LO activity, showed that IL-12 impairs GSIS at both low and high levels of glucose in the MIN6 beta cell line. These studies point to downstream effects of 12/15-LO expression in the pancreas. Recent data from our group show a direct role for IL-12 and its receptors in the development of islet inflammation. These studies were confirmed in several beta cell lines [27].

Our work suggests that macrophage and islet 12/15-LO both play a role in the development of the inflammatory processes in the pancreas. Inflammation appears to be required for the initiation of diabetes in NOD mice [39], and 12/15-LO may play a vital role in the development of this inflammation. Indeed, a recent study has shown that inhibition of 12-lipoxygenase decreases NADPH-oxidase 1, as well as endogenous reactive oxygen species, which protects beta cell lines and cultured islets from apoptosis [40]. As 12-lipoxygenase is upstream of these mediators, it is a strong therapeutic candidate. Additional studies are needed to define the particular role of 12/15-LO in the islet as compared to the macrophage. Macrophage-specific and islet-specific deletions of Alox15 in NOD will be helpful in clarifying this issue.

Overall, our data point to a model in which 12/15-LO affects islet health early in development. Since 12/15-LO is involved in signaling leading to ER stress, it is possible that early unknown events trigger the inflammatory signaling cascade [41], which could cause the recruitment and activation of macrophages. As macrophages are also a source of 12/15-LO, their production could exacerbate the cycle, leading to additional inflammation. Since human islets express 12/15-LO, it is possible that targeting this enzyme may provide a new therapeutic option to help maintain beta cell mass in T1D.

### Table 1. mRNA expression of molecular indicators of islet health in NOD and NOD-Alox15null mouse islets.

| Gene       | 4 weeks | 8 weeks | 12 weeks |
|------------|---------|---------|---------|
|            | NOD     | Alox15null | NOD     | Alox15null | NOD     | Alox15null | NOD |
| GLUT2      | 1.0±0.6b | 1.2±0.4b | 0.5±0.3b | 0.5±0.5b | 2.8±0.5b | 0.3±0.1 |
| Pdx1       | 1.0±0.5b | 1.0±0.2bc | 2.2±0.3bc | 0.2±0.07 | 4.3±0.6b | 0.2±0.04 |
| UCP2       | 1.0±2.1a | 1.7±1.2 | 1.3±0.06 | 1.0±0.07b | 1.2±0.6 | 4.0±1.6 |

Data are shown as fold change based on control (4 week old NOD-Alox15null samples) and normalized to Actin. All samples were run in triplicate with an (n = 4). *p<0.05 vs age-matched groups (i.e., 8 wk NOD vs. 8 wk NOD-Alox15null), p<0.05 vs. 12 week time point in strain-matched groups (i.e., 8 wk NOD vs. 12 wk NOD); p<0.05 vs. 8 week time point in strain-matched groups (i.e., 4 wk NOD vs. 8 wk NOD).

doi:10.1371/journal.pone.0056763.t001
Figure 6. Gene expression of pro-inflammatory cytokines related to the IL-12/12/15LO axis. A) mRNA expression of IL-12Rβ2, B) IL-12Rβ1, C) IL-12p35, D) IL-12p40, E) STAT4, F) IFN-γ, G) TNF-α, and H) IL-1β in 4, 8, and 12 week old NOD and NOD-Alox15null mice islets. All samples were run in triplicate with an (n = 6). Data are expressed as fold reduction compared to their aged matched control (NOD). *p<0.05 and **p<0.005 for NOD vs. NOD-Alox15null at the same age. Filled bars represent NOD and open bars represent NOD-Alox15null samples.
doi:10.1371/journal.pone.0056763.g006
Figure 7. Cytokine production in triple cytokine-treated βTC3 cells. βTC3 cells were treated with a triple cytokine cocktail (IFN-γ, TNF-α, and IL-1β). Cytokine production was measured, and data are expressed as the fold change over paired untreated controls, with n = 8 for each sample. These data represent 3 separate experiments. doi:10.1371/journal.pone.0056763.g007

Supporting Information

Figure S1 12/15-LO mRNA expression in NOD tissues (Lymph nodes (A), fat and spleen (B)). N = 6 per time point. Data are representative of 3 experiments. (TIFF)

Table S1 Th17 array of NOD and NOD-Alox15null islets at 8, 12, and 16 weeks. N = 3 per group, per time point. (DOCX)

Acknowledgments

The authors would like to acknowledge Rebekah Raab, Department of Internal Medicine at EVMS, for her excellent animal husbandry, and Kendall Leone for her superb technical help. We would also like to acknowledge the EVMS Flow Cytometry Core Facility. Additional gratitude is extended to Dr. Anca Dobrian, Department of Physiology at EVMS, for her help with data analysis.

Author Contributions

Critical reading/editing of manuscript: SAT KM BKC NAM SKC. Conceived and designed the experiments: SGM SAT KM NSK TDC MM DATF RGM JLN MAM. Performed the experiments: SGM SAT KM NSK TDC NAM SKC MAM BKC MM. Contributed reagents/materials/analysis tools: TDC MM DATF RGM JLN MAM. Wrote the paper: SGM SAT KM NSK NAM SKC MAM BKC. Analyzed the data: SGM NAM SKC MM DATF RGM JLN MAM.

References

1. Ziegler A-G, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunology 32: 468–478.
2. Todd JA (2010) Etiology of type 1 diabetes. Immunology 32: 457–467.
3. Anderson MS, Bluestone JA (2005) The NOD mouse: a model of immune dysregulation. Ann Rev Immunol 23: 447–483.
4. McDuffie M, Maybee NA, Keller SR, Stevens BK, Garmey JC, et al. (2008) Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 57: 199–208.
5. Kuhn H, O’Donnell VB (2006) Inflammation and immune regulation by 12/15-lipoxygenases. Prog in Lipid Res 45: 334–356.
6. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, et al. (2011) Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 50: 115–131.
7. Soberman RJ, Harper TW, Betteridge D, Lewin RA, Auen TF (1983) Characterization and separation of the arachidonic acid 5-lipoxygenase and linoleic acid ω-6-lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. J Biol Chem 260: 4508–4515.
8. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL (2005) Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetes 54: 486–495.
9. Middleton MK, Rubenstein T, Pure E (2006) Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/15-lipoxygenase. J Immunol 176: 265–274.
10. Chakrabarti SK, Wen Y, Dobrian AD, Cole BK, Ma Q, et al. (2011) Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 300: E175–E187.
11. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, et al. (2004) Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 22: 191–200.
12. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, et al. (2002) Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277: 33530–33536.
13. Dioszeghy V, Rosas M, Macek BH, Colmont C, Topple N, et al. (2008) 12/15-lipoxygenase regulates the inflammatory response to bacterial products in vivo. J Immunol 181: 6314–6324.
14. Bleich D, Chen S, Gu J-L, Nadler JL (1998) The role of 12-lipoxygenase in pancreatic beta-cells. Int J Mol Med 1: 265–272.
15. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, et al. (2010) 12-lipoxygenase products reduce insulin secretion and b-cell viability in human islets. J Clin Endocrinol Metab 95: 887–893.
16. Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, et al. (in press) Islet b-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the non-obese diabetic mouse model. Diabetes.
17. Tersey SA, Cole BK, Nadler JL, Mirrilla RG (2011) Pancreas-specific deletion of 12-lipoxygenase protects against islet dysfunction in mouse models of cytokine-mediated diabetes. Diabetes 61: 559–568.
18. Guest PC, Rhodes CJ, Hutson JC (1989) Regulation of the biosynthesis of insulin-secretory-granule proteins. Coordinate translational control is exerted on some, but not all, granule matrix constituents. Biochem J 257: 431–437.
19. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL (2009) 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity 17: 1657–1663.
20. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, et al. (2004) PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 114: 828–836.
21. Francis J, Chakrabarti SK, Garmey JC, Mirmira RG (2005) Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription. J Biol Chem 280: 36244–36253.

22. Maier B, Oghara T, Trace AP, Tersey SA, Robbins RD, et al. (2010) The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest 120: 2156–2170.

23. Morris MA, McDuffie M, Nadler JL, Lcy K (2011) Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Autoimmunity 44: 115–128.

24. Bendelac A, Carandeu C, Boitard C, Bach J-F (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates: requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 165: 823–832.

25. Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, et al. (1993) Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36: 1139–1145.

26. Wolk R, Sabat R (2006) Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine & Growth Factor Rev 17: 367–380.

27. Taylor-Fishwick DA, Weaver JR, Grzesik W, Chakrabarti SK, Green-Mitchell SM, et al. (2012) Production and function of IL-12 in islets and beta cells. Diabetologia ePah ahead of print.

28. Wen Y, Gu J, Vandenhoff GE, Liu X, Nadler JL (2008) Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am J Physiol Heart Circ Physiol 294: H1933–1938.

29. Boyton RJ, Davies S, Marden C, Fantino C, Reynolds C, et al. (2005) Stat4-null non-obese diabetic mice: protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. Int Immunol 17: 1157–1163.

30. Cetkovic-Cvrlje M, Uckun FM (2005) Effect of targeted disruption of signal transducer and activator of transcription Stat4 and Stat6 genes on the autoimmune diabetes development induced by multiple low doses of streptozotocin. Clin Immunol 114: 299–306.

31. Yang Z, Chen M, Fialkow LB, Elliott JD, Wu R, et al. (2003) Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 1005: 409–411.

32. Kino HS, Chung DH (2012) TLR-4 mediated IL-12 production enhances IFN-gamma and IL-1 beta production, which inhibits TGF-beta production and promotes antibody-induced joint inflammation. Arthritis Research and Therapy 14: R210.

33. Zhu J, Jankovic D, Oher AJ, Wei G, Sharma S, et al. (2012) The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37: 660–673.

34. Li L, He Q, Garland A, Yi Z, Aybar LT, et al. (2009) Beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct. J Immunol 183: 7585–7591.

35. Iz-Ludlow D, Lighthot Y, Parker M, Xue S, Wasserfall C, et al. (2011) Progressive erosion of beta-cell function preceds the onset of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes 60: 2086–2091.

36. Hagman DK, Latour MG, Chakrabarti SK, Fontes G, Amory J, et al. (2008) Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. Diabetes 57: 424–431.

37. Berardi MJ, Shah WM, Harrison SC, Chou JI (2011) Minichondrial uncoupling protein 2 structure determined by NMR molecular fragment searching. Nature 476: 109–113.

38. Estil les E, Tellez N, Soler J, Montanya E (2009) High sensitivity of beta-cell replication to the inhibitory effects of interleukin-beta modulation by adenoviral overexpression of IGFI2 in rat islets. J Endocrinol 203: 53–63.

39. Carrington EM, Kos C, Zhan Y, Krishnamurthy B, Allison J (2011) Reducing or increasing b-cell apoptosis without inflammation does not affect diabetes initiation in neonatal NOD mice. Eur J Immunol 41: 2230–2247.

40. Weaver JR, Holmes TR, Imay Y, Jadiab A, Kenyon V, et al. (2012) Integration of pro-inflammatory cytokine, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endo 356: 88–95.

41. Cole BK, Kahn NS, Green-Mitchell SM, Leone KA, Raab RM, et al. (2012) 12-lipoxygenase signaling in the endoplasmic reticulum stress response. Am J Physiol Endocrinol Metab 302: E654–E665.